Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Chemoradiotherapy for Anus-Preservation in Low Rectal Adenocarcinoma
NCT05669092Phase 3Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Nov 2022
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in rectal adenocarcinoma, sponsored by Zhejiang Cancer Hospital. Started Nov 2022; status: recruiting.
02
Drugs
toripalimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05669092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05669092.